sciencesgate.com Report : Visit Site

Technical data of the sciencesgate.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host sciencesgate.com. Currently, hosted in France and its service provider is OVH SAS .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

home artificial intelligence news of the week (2018) uncategorized red-blood-cell “hitchhikers” transport drugs to specific targets august 3, 2018 uncategorized a new drug-delivery technology which uses red blood cells ( rbc s) to shuttle nano-scale drug carriers , called rbc-hitchhiking ( rh ), has been found in animal models to dramatically increase the concentration of drugs ferried precisely to selected organs , according to a study published in nature communications this month by researchers from the perelman school of medicine at the university of pennsylvania . this proof-of-principle study points to ways to improve drug delivery for some of the nation’s biggest killers , such as acute lung disease , stroke, and heart attack . “ the vast majority of drugs fail because they spread throughout the body, landing in nearby organs where they can cause intolerable side effects, as opposed to directly targeting the areas that are really in need, ” said first author jake brenner, md, phd, an assistant professor of pulmonary medicine and critical care and of pharmacology. “ by massively increasing the drug concentrations that are hitting specific tissues, the rbc hitchhikers should decrease potential side effects and improve the efficacy of drugs delivered to target organs .” the team showed that rh can safely transport nano-scale carriers of drugs to chosen organs by targeted placement of intravascular catheters , in mice, pigs, and in ex vivo human lungs , without causing rbc or organ toxicities . “ red blood cells are a particularly attractive carrier due to their biocompatibility and known safety in transfusions, ” said senior author vladimir muzykantov, md, phd , a professor of systems pharmacology and translational therapeutics. “ in just a few short years since we began this work, we are now on the brink of mapping out ways to test it in clinical trials .” the researchers found that rh drug carriers injected intravenously increased drug uptake by about 40-fold in the lungs compared to absorption of freely circulating drug carriers in blood . in addition, injecting the rh drug carriers into the carotid artery (a major blood vessel in the neck that delivers blood to the brain , neck , and face ) delivers 10 percent of the injected dose to the brain , which is about 10 times higher than what is achieved through older methods such using antibodies to guide drugs to their intended targets. such impressive drug delivery to the brain could be used to treat acute strokes , the fourth leading cause of death in the u.s. development of rh technology has also revealed a potentially fundamental process that hold enormous clinical promise. “ the body’s largest surface area of cell-to-cell interaction is observed between red blood cells and blood vessel linings, so it is intriguing to think that our rh technology has uncovered a phenomenon in which rbcs naturally transport cargo on their surfaces ,” said muzykantov. source: https://www.pennmedicine.org/ read more breakthrough in the fight against alzheimer’s august 2, 2018 uncategorized eisai co ., a company located in tokyo, and biogen inc. in cambridge, united states, announced positive topline results from the phase ii study with ban2401 , an anti-amyloid beta protofibril antibody , in 856 patients with early alzheimer’s disease. the study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in alzheimer’s disease composite score ( adcoms ) and on reduction of amyloid accumulated in the brain as measured using amyloid-pet (positron emission tomography). study 201 is a placebo -controlled, double-blind , parallel-group, randomized study in 856 patients with mild cognitive impairment ( mci ) due to alzheimer’s disease ( ad ) or mild alzheimer’s dementia (collectively known as early alzheimer’s disease ) with confirmed amyloid pathology in th e brain . efficacy was evaluated at 18 months by predefined conventional statistics on adcoms , which combines items from th e alzheimer’s disease assessment scale – cognitive subscale ( adas-cog ), the clinical dementia rating sum of boxes ( cdr-sb ) scale and the mini-mental state examination ( mmse ) to enable sensitive detection of changes in early ad symptoms . patients were randomized to five dose regimens , 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly and 10 mg/kg biweekly, or placebo . topline results of the final analysis of the study demonstrated a statistically significant slowing of disease progression on the key clinical endpoint ( adcoms ) after 18 months of treatment in patients receiving the highest treatment dose (10 mg/kg biweekly) as compared to placebo. results of amyloid pet analyses at 18 months , including reduction in amyloid pet standardized uptake value ratio ( suvr ) and amyloid pet image visua l read of subjects converting from positive to negative for amyloid in the brain , were also statistically significant at this dose. dose-dependent changes from baseline were observed across the pet results and the clinical endpoints. further, the highest treatment dose of ban2401 began to show statistically significant clinical benefit as measured by adcoms as early as 6 months including at 12 months. source: https://www.eisai.com/ read more electric car: how to make super-fast charging batteries august 1, 2018 uncategorized researchers have identified a group of materials that could be used to make even higher power batteries . the researchers, from the university of cambridge , used materials with a complex crystalline structure and found that lithium ions move through them at rates that far exceed those of typical electrode materials , which equates to a much faster-charging battery . although these materials , known as niobium tungsten oxides , do not result in higher energy densities when used under typical cycling rates , they come into their own for fast charging applications. additionally, their physical structure and chemical behaviour give researchers a valuable insight into how a safe , super-fast charging battery could be constructed, and suggest that the solution to next-generation batteries may come from unconventional materials . many of the technologies we use every day have been getting smaller , faster and cheaper each year – with the notable exception of batteries . apart from the possibility of a smartphone which could be fully charged in minutes , the challenges associated with making a better battery are holding back the widespread adoption of two major clean technologies : electric cars and grid-scale storage for solar power . “ we’re always looking for materials with high-rate battery performance, which would result in a much faster charge and could also deliver high power output, ” said dr kent griffith, a postdoctoral researcher in cambridge ’s department of chemistry and the paper’s first author. in their simplest form, batteries a re made of three components : a positive electrode , a negative electrode and an electrolyte . when a battery is charging , lithium ions are extracted from the positive electrode and move through the crystal structure and electrolyte to the negative electrode , where they are stored . the faster this process occurs, the faster the battery can be charged . in the search for new electrode materials , researchers normally try to make the particles smaller . “ the idea is that if you make the distance the lithium ions have to travel shorter, it should give you higher rate performance ,” said griffith. “ but it’s difficult to make a practical battery with nanoparticles: you get a lot more unwanted chemical reactions with the electrolyte, so the battery doesn’t last as long, plus it’s expensive to make. ” “ nanoparticles can be tricky to make, which is why we’re searching for materials that inherently have the properties we’re looking for even when they are used as comparatively large micron-sized particles. this m

URL analysis for sciencesgate.com

http://www.sciencesgate.com/index.php/2018/05/02/how-to-hear-art/#more-127
http://www.sciencesgate.com/index.php/2018/07/25/brain-function-partly-replicated-by-nanomaterials/#more-549
http://www.sciencesgate.com/index.php/2018/06/22/mass-production-of-low-cost-solar-cells/#more-402
http://www.sciencesgate.com/index.php/2018/05/28/3d-printed-house-built-in-24-hours-for-4000/
http://www.sciencesgate.com/index.php/2018/06/06/new-combination-to-eradicate-staph-aureus/#more-290
http://www.sciencesgate.com/index.php/2018/04/10/hello-world/#more-1
http://www.sciencesgate.com/index.php/2018/06/01/orthodontic-surgery-without-incision/
http://www.sciencesgate.com/index.php/2018/06/12/genetic-codes-mapping-of-3000-dangerous-bacteria/
http://www.sciencesgate.com/index.php/2018/07/04/quantum-computer-controls-one-billion-electrons-per-second-one-by-one/#more-469
http://www.sciencesgate.com/index.php/2018/06/08/electric-car-for-megacities/#more-301
http://www.sciencesgate.com/index.php/2018/06/15/electric-road-for-electric-cars/#more-354
http://www.sciencesgate.com/index.php/2018/04/10/hello-world/#comments
http://www.sciencesgate.com/index.php/2018/06/26/brain-metals-drive-alzheimers-progression/#more-416
http://www.sciencesgate.com/index.php/2018/05/07/harvesting-clean-hydrogen-fuel-through-artificial-photosynthesis/#more-149
http://www.sciencesgate.com/index.php/2018/05/29/nanoparticles-cross-the-blood-brain-barrier-shrink-glioblastoma-tumors/
theengineer.co.uk
uopnews.port.ac.uk
qmul.ac.uk
swansea.ac.uk
sussex.ac.uk
cam.ac.uk
warwick.ac.uk
manchester.ac.uk
dailymail.co.uk
geneticmodificationinplants.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: SCIENCESGATE.COM
Registry Domain ID: 22069335_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ovh.com
Registrar URL: http://www.ovh.com
Updated Date: 2018-02-25T21:00:32Z
Creation Date: 2000-03-10T14:48:35Z
Registry Expiry Date: 2020-03-10T13:48:35Z
Registrar: OVH
Registrar IANA ID: 433
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS13.OVH.NET
Name Server: NS13.OVH.NET
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2018-08-19T05:46:05Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR OVH

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =sciencesgate.com

  PORT 43

  TYPE domain

DOMAIN

  NAME sciencesgate.com

  CHANGED 2018-02-25

  CREATED 2000-03-10

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  DNS13.OVH.NET 213.251.188.132

  NS13.OVH.NET 213.251.128.132

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .